What is the difference between myo-inositol and D-chiro-inositol?

Myo-inositol and D-chiro-inositol are isomers with distinct roles in insulin signaling. Myo-inositol mediates FSH signaling and is the predominant tissue form. D-chiro-inositol mediates downstream insulin signaling via glycan mediators (PMID 20811656). In a randomized trial in women with PCOS, the 40:1 physiological ratio — which mirrors serum concentrations — outperformed the other ratios tested, including D-chiro-inositol alone (PMID 31298405).

What dose of myo-inositol is used in studies?

Most clinical trials use 2–4 g of myo-inositol daily, often in divided doses. The 40:1 combination (e.g., 4 g myo-inositol + 100 mg D-chiro-inositol) has been studied in women with PCOS, where a 3-month randomized trial reported improvements in hormonal and metabolic markers (PMID 31298405). Those trials enrolled women whose markers were elevated at baseline, and across the wider trial base the evidence remains mixed and not yet conclusive (PMID 38163998).

Is inositol useful for anxiety or mood?

Some small clinical trials have investigated high-dose myo-inositol for mood and anxiety. Evidence is preliminary and findings are mixed. The hormonal/metabolic and the mood-related evidence bases are distinct: the larger body of research has been conducted in women with PCOS and in insulin-signaling contexts, not in mood. Myo-inositol is not a treatment for any mood or hormonal condition — consult your healthcare provider.

Can inositol be taken safely long-term?

Myo-inositol is generally well tolerated at doses studied (up to 4 g/day) with gastrointestinal effects being the most common side effect. Long-term safety data beyond 6 months are limited. Consult a healthcare provider, especially if pregnant or taking medications affecting blood sugar.

Best Inositol Form: Which Should You Take?

Myo-inositol — particularly in a physiological 40:1 ratio with D-chiro-inositol — is the form with the most clinical research behind it, most of it conducted in women with PCOS, for hormonal balance, insulin signaling, and ovarian function.

Updated 2026 · Reviewed by Dr. Brennan Commerford, D.C.

All Forms Ranked by Evidence

Several forms share the top tier: their absorption profiles are statistically comparable in the published research, so they collapse into one band rather than splitting hairs over differences too small to matter clinically. Within the tier, the most-cited form is listed first.

1
95/ 100· Top TierBest by EvidenceFF Preferred
D-Chiro-Inositol
Form: D-Form
2
95/ 100· Top TierFF Preferred
Inositol
Form: Myo-inositol
—
Verification pending
Phosphatidylinositol
Form: Phospholipid
Phosphatidylinositol — Phosphatidylinositol is one form of this compound. Limited direct human-PK evidence for this specific form. We grade forms only where form-specific human pharmacokinetic evidence exists; this form does not yet meet that bar, so we do not assign it a benefit rating.

Editorial note

A randomized trial in 56 women with PCOS (8 per group) found a 40:1 myo-inositol:D-chiro-inositol ratio supported ovarian function parameters better than D-chiro-inositol alone (PMID 31298405). Myo-inositol is the predominant physiological form, mediating insulin signal transduction and FSH activity. Two further trials — a double-blind trial in 42 women with PCOS (PMID 19499845) and a single-arm study of a myo-inositol combination formulation in 24 normal-weight women with PCOS (PMID 24606639) — reported improvements in hormonal markers that were elevated at baseline. The overall evidence is mixed: a 2024 systematic review of 30 trials informing the international PCOS guidelines concluded that support for inositol in PCOS is limited and inconclusive (PMID 38163998), and a meta-analysis of 8 randomized trials in women with PCOS undergoing ICSI found no clear effect on pregnancy rates (PMID 28756130). We include inositol for maintenance of normal hormonal and metabolic function — not as a treatment for PCOS or any condition — an application these trials do not measure. Consult your healthcare provider before use.

All Forms Compared

Myo-inositol

Best For

Healthy hormonal balance, insulin sensitivity, ovarian function

The most abundant inositol isomer in human tissue. Clinical trials at 2–4 g/day, conducted in women with PCOS, report support for ovarian function and FSH activity — particularly in a 40:1 ratio with D-chiro-inositol (PMID 31298405, PMID 19499845). Across the wider trial base the evidence remains mixed and not yet conclusive (PMID 38163998).

D-Chiro-Inositol (DCI)

Best For

Insulin signaling support, used in combination with myo-inositol

D-chiro-inositol glycans mediate specific insulin signaling pathways (PMID 20811656). In the ratio trial in women with PCOS, the 40:1 combination with myo-inositol outperformed D-chiro-inositol taken alone (PMID 31298405) — though across the wider trial base the evidence for inositol in PCOS remains mixed and not yet conclusive (PMID 38163998).

IP6 (Inositol Hexaphosphate)

Best For

Antioxidant support, iron chelation research applications

IP6 (inositol hexaphosphate) functions primarily as an antioxidant and phytate chelator rather than an insulin sensitizer. Controlled-trial evidence for IP6 is distinct from myo-inositol studies.

Phospholipid

Best For

Cell membrane support as part of a phospholipid complex

Inositol as phosphatidylinositol plays a structural role in cell membranes. It is not the form used in the hormonal or metabolic clinical trials described above.

Frequently Asked Questions

What is the difference between myo-inositol and D-chiro-inositol?: Myo-inositol and D-chiro-inositol are isomers with distinct roles in insulin signaling. Myo-inositol mediates FSH signaling and is the predominant tissue form. D-chiro-inositol mediates downstream insulin signaling via glycan mediators (PMID 20811656). In a randomized trial in women with PCOS, the 40:1 physiological ratio — which mirrors serum concentrations — outperformed the other ratios tested, including D-chiro-inositol alone (PMID 31298405).
What dose of myo-inositol is used in studies?: Most clinical trials use 2–4 g of myo-inositol daily, often in divided doses. The 40:1 combination (e.g., 4 g myo-inositol + 100 mg D-chiro-inositol) has been studied in women with PCOS, where a 3-month randomized trial reported improvements in hormonal and metabolic markers (PMID 31298405). Those trials enrolled women whose markers were elevated at baseline, and across the wider trial base the evidence remains mixed and not yet conclusive (PMID 38163998).
Is inositol useful for anxiety or mood?: Some small clinical trials have investigated high-dose myo-inositol for mood and anxiety. Evidence is preliminary and findings are mixed. The hormonal/metabolic and the mood-related evidence bases are distinct: the larger body of research has been conducted in women with PCOS and in insulin-signaling contexts, not in mood. Myo-inositol is not a treatment for any mood or hormonal condition — consult your healthcare provider.
Can inositol be taken safely long-term?: Myo-inositol is generally well tolerated at doses studied (up to 4 g/day) with gastrointestinal effects being the most common side effect. Long-term safety data beyond 6 months are limited. Consult a healthcare provider, especially if pregnant or taking medications affecting blood sugar.

Ready to formulate with Myo-inositol?

Build your personalized formula with research-backed dosing.

Start My Formula

Deep dive: Myo-inositol research

Full ingredient spotlight with citations

View spotlight

FormulaForge formulates and sells supplements containing the ingredients discussed on this page. Our formulary recommendations are based on peer-reviewed bioavailability research. All cited studies are independently verifiable.